2-Bromo-1-(4-fluoro-phenyl)-2-pyridin-4-yl-ethanone | 216529-31-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Bromo-1-(4-fluoro-phenyl)-2-pyridin-4-yl-ethanone
• 英文别名: 1-fluoro-4-(4'-pyridylbromoacetyl)benzene；1-fluoro-4-(pyridin-4-ylbromoacetyl)benzene；1-fluoro-4-(4-pyridylbromoacetyl)benzene；2-Bromo-1-(4-fluorophenyl)-2-pyridin-4-ylethanone
• CAS: 216529-31-6
• 化学式: C₁₃H₉BrFNO
• 分子量: 294.123
• InChiKey: LEZFFXJTSQEBEB-UHFFFAOYSA-N

物化性质

• 沸点：
  388.5±32.0 °C(Predicted)
• 密度：
  1.523±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Bromo-1-(4-fluoro-phenyl)-2-pyridin-4-yl-ethanone 在 bis(1,5-cyclooctadiene)nickel (0) 、 copper(l) iodide 、 copper(ll) sulfate pentahydrate 、 硫酸 、 1,2-双(二苯基膦基)苯 、 四丁基氟化铵 、 sodium ascorbate 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 0.58h， 生成
  参考文献：
  名称：

  Syntheses and structure–activity relationships for some triazolyl p38α MAPK inhibitors

  摘要：

  The design, synthesis and biological evaluation of novel triazolyl p38 alpha MAPK inhibitors with improved water solubility for formulation in cationic liposomes (SAINT-O-Somes) targeted at diseased endothelial cells is described. Water-solubilizing groups were introduced via a 'click' reaction of functional azides with 2-alkynyl imidazoles and isosteric oxazoles to generate two small libraries of 1,4-disubstituted 1,2,3-triazolyl p38 alpha MAPK inhibitors. Triazoles with low IC50 values and desired physicochemical properties were screened for in vitro downregulation of proinflammatory gene expression and were formulated in SAINT-O-Somes. Triazolyl p38 alpha MAPK inhibitor 88 (IC50 = 0.096 mu M) displayed the most promising in vitro activity. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.034
• 作为产物：
  描述：

  对氟苯甲酸乙酯 在 溴 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 2-Bromo-1-(4-fluoro-phenyl)-2-pyridin-4-yl-ethanone
  参考文献：
  名称：

  Synthesis and SAR of 2,3-diarylpyrrole inhibitors of parasite cGMP-dependent protein kinase as novel anticoccidial agents

  摘要：

  Several analogs of 2,3-diaryl pyrroles were synthesized and evaluated as inhibitors of Eimeria tenella cGMP-dependent protein kinase and in. in vivo anticoccidial assays. A 4-fluorophenyl group enhances both in vitro and in Vivo activities. The most potent analogs are the-5-(N-methyl, N-ethyl, and N-methylazetidine methyl) piperidyl derivatives 12, 23, and 34. These compounds have a broad spectrum of activity. Based on the in vivo efficacy and cost of synthesis, the N-ethyl analog 23 was chosen as a novel anticoccidial agent for a field trial. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.060

文献信息

• Substituted pyrazoles as p38 kinase inhibitors
  申请人：G.D. Searle & Company

  公开号：US06514977B1

  公开（公告）日：2003-02-04

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.

  描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。特别感兴趣的化合物由下式IA定义： 其中R1、R2、R3和R4如规范中所述。
• Antiinflammatory activity of 5,6-diaryl-2,3-dihydroimidazo[2,1-b]thiazoles. Isomeric 4-pyridyl and 4-substituted-phenyl derivatives
  作者：I. Lantos、P. E. Bender、K. A. Razgaitis、B. M. Sutton、M. J. DiMartino、D. E. Griswold、D. T. Walz

  DOI：10.1021/jm00367a014

  日期：1984.1

  Isomeric 5(6)-(4-pyridyl)- and 6(5)-(4-substituted-phenyl)-2,3-dihydroimidazo[2,1-b]thiazoles were prepared by a mixed benzoin-imidazothione route, and their structures were assigned by spectral comparison to compounds of established substitution pattern. The structural assignment was confirmed by X-ray analysis. Examination of the compounds for antiinflammatory activity by an adjuvant arthritic rat

  通过混合安息香-咪唑并硫醇途径制备异构5（6）-（4-吡啶基）-和6（5）-（4-取代苯基）-2,3-二氢咪唑并[2,1-b]噻唑。通过光谱比较将它们的结构分配给已建立取代模式的化合物。通过X射线分析确认了结构分配。通过佐剂关节炎大鼠测定法对化合物的抗炎活性的检查显示，一个类似系列的化合物的功效显着高于其异构体。在恶唑酮诱导的接触敏感性模型中反映出，这种选择性与刺激细胞介导的免疫能力平行。提出了需要至少三个相互作用位点的药物-受体复合物。
• [EN] SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS<br/>[FR] PYRAZOLES SUBSTITUES UTILISES COMME INHIBITEURS DE LA KINASE p38
  申请人：SEARLE & CO

  公开号：WO2000031063A1

  公开（公告）日：2000-06-02

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R?1, R2, R3 and R4¿ are as described in the specification.

  本文描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。 特别感兴趣的化合物由公式（IA）定义，其中R?1，R2，R3和R4¿如规范中所述。
• Heteroaryl-cyclic acetals
  申请人：Collis Alan

  公开号：US20050090501A1

  公开（公告）日：2005-04-28

  Compounds of formula (I) are described in which Het is a five or six membered heteroaromatic ring of the formula in which one of R 1 and R 2 is optionally substituted heteroaryl and the other is optionally substituted heteroaryl or optionally substituted aryl; X 1 is a bond, X 3 and X 4 are each independently N or C and X 2 and X 5 are independently CH, N, NH, O or S; or X 3 and X 4 are C, one of X 1 , X 2 and X 5 is N and the others are N or CH; but excluding compounds in which X 1 is a bond, one of X 2 and X 5 is N and the other is NH and X 3 and X 4 are both C; R 3 represents a group -L 1 -R 6 ; R 4 represents hydrogen, alkyl or hydroxyalkyl; or R 3 and R 4 , when attached to the same carbon atom, may form with the said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ring or a group C═CH 2 ; R 5 represents hydrogen or alkyl; and m is zero or an integer 1 or 2; and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates of compounds of formula (I) and N-oxides thereof, and their prodrugs. The compounds are TNF inhibitors and are useful as pharmaceuticals.

  描述了式(I)化合物，其中Het是式的五元或六元杂环芳香环：其中R1和R2中的一个是可选取代的杂芳基，另一个是可选取代的杂芳基或可选取代的芳基；X1是键，X3和X4分别独立地是N或C，X2和X5独立地是CH、N、NH、O或S；或者X3和X4是C，X1、X2和X5中的一个是N，其他是N或CH；但不包括其中X1是键，X2和X5中的一个是N，另一个是NH，X3和X4都是C的化合物；R3表示一个-L1-R6基团；R4表示氢、烷基或羟基烷基；或者当附加到同一个碳原子时，R3和R4可以与所述碳原子形成环状烷基、环状烯基或杂环烷基环或C═CH2基团；R5表示氢或烷基；m为零或整数1或2；以及其N-氧化物和其前药；化合物的式(I)和其N-氧化物的药学上可接受的盐和溶剂；这些化合物是TNF抑制剂，可用于制药。
• Medicinal compositions
  申请人：Ohkawa Shigenori

  公开号：US20050080113A1

  公开（公告）日：2005-04-14

  The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.

  本发明涉及一种用于预防或治疗疼痛的药剂，一种用于抑制成骨细胞活化的药剂，以及一种抑制成骨细胞形成的抑制剂，其中包含p38 MAP激酶抑制剂和/或TNF-α生产抑制剂。